Jonathan Chernoff, MD, PhD

Cancer Center Director, Stanley P. Reimann Chair in Oncology Research

Calculated based on number of publications stored in Pure and citations from Scopus
Calculated based on number of publications stored in Pure and citations from Scopus
Calculated based on number of publications stored in Pure and citations from Scopus
1983 …2024

Research activity per year

Personal profile

Personal profile

As Cancer Center Director at Fox Chase Cancer Center, Jonathan Chernoff works with Temple University Health System and Temple University peers to lead Fox Chase into the future of cancer care. With decades of research expertise, Chernoff has helped Fox Chase focus on the areas that best leverage the institution’s enhanced strengths in scientific development: translational research, precision medicine, epigenetics, signaling reprograming, immunotherapy, hematologic malignancies, and cancer disparities. 

A molecular oncologist and board-certified medical oncologist, Chernoff joined Fox Chase in 1991. In addition to helping define the strategic direction for Fox Chase research, he has made fundamental contributions in his own laboratory, which focuses on factors that control cell growth and movement, including oncogenes and anticancer or tumor-suppressor genes. He currently holds the Stanley P. Reimann Chair in Oncology Research. Chernoff has trained dozens of postdoctoral and graduate students at Fox Chase. He serves as an adjunct professor for the Drexel University School of Medicine and for the University of Pennsylvania, and is a member of the Cancer Signaling and Epigenetics research program at Fox Chase.

In addition to these roles, Chernoff has served on multiple external advisory boards, including the Scientific Advisory Board for Nexgenix Pharmaceuticals, as well as advisory boards for Genentech, Novartis Pharmaceuticals, and the New York University (Perlmutter) Cancer Center, among others. He has also taken on roles for multiple committees and programs within Fox Chase.

Chernoff earned his bachelor’s degree in molecular biophysics and biochemistry from Yale College and his medical degree and doctorate from the Mount Sinai School of Medicine in New York. He completed his residency in internal medicine at the University Health Center of Pittsburgh and a clinical fellowship in medical oncology at Johns Hopkins Oncology Center. He then held a postdoctoral fellowship in cellular and developmental biology at Harvard University before coming to Fox Chase.

External positions

Scientific Advisory Board, Novo Nordisk

Jan 1 2019Dec 31 2020

External Advisory Board, University of Miami Epigenetics

Jan 1 2017 → …

Scientific Advisory Board, Tarsa

Jan 1 2013Dec 31 2017

External Advisory Board, Case Western Cancer Signaling Program

Jan 1 2012Dec 31 2014

Scientific Advisory Board, Pharma-Arava

Jan 1 2012Dec 31 2017

Co-Chair, NF2 Preclinical consortium

Jan 1 2011Dec 31 2012

External Advisory Board, NYU Cancer Institute

Jan 1 2011Dec 31 2016

Advisory Board, Genentech

Jan 1 2008Dec 31 2013

Advisory Board, Novartis Pharmaceuticals

Jan 1 2008Dec 31 2011

Adjunct Professor, Drexel University School of Medicine

Jan 1 2004 → …

Scientific Advisory Board, Nexgenix Pharmaceuticals

Jan 1 2004Dec 31 2011

Adjunct Assistant Professor, University of Pennsylvania

Jan 1 1996 → …


Dive into the research topics where Jonathan Chernoff is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or